Fetal chromosome aberrations with colchicine
- PDF / 154,470 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 19 Downloads / 243 Views
1
Fetal chromosome aberrations with colchicine The fetuses of patients treated with colchicine have an increased risk of chromosome aberrations, according to study results reported in Rheumatology, although "the absolute risk is relatively low". The study retrospectively searched Israel’s’ Ministry of Health computerised database for cases referred for invasive chromosomal testing due to parental colchicine treatment in 2003–2019. "A marked decrease due to this indication was noted over the years", note the authors. The 755 exposed pregnancies were compared with 2752 low-risk pregnancies (controls). Chromosomal aberrations were detected in 5 colchicine recipients and 6 controls (0.66% vs 0.2%, relative risk 2.2; 95% CI 1.1, 4.2). Aberrations included: 47,XXY (Klinefelter syndrome); 45,X0 (Turner syndrome); 47,XYY; trisomy 21; trisomy 13 mosaicism; 2q gain mosaicism; and Xq26.2-q28 deletion. A literature search detected four studies with 740 pregnancies, which were all conducted in Israel and published in English. The chromosome aberration rate was 1.5% in one study, and nil in three studies. However, study quality was assessed as low, and meta-analysis was not performed. "The results of our observational study support the concern that colchicine treatment may be associated with increased risk for fetal chromosome aberrations", note the authors, although the absolute risk is estimated as "1 in every 151 pregnancies". They add that "it seems the recommendation to perform invasive testing in colchicine-exposed pregnancies should be the prudent approach". Singer A, et al. Colchicine treatment increases the risk for fetal chromosomal aberrations-an observational study and systematic literature review. Rheumatology : 12 Nov 803519180 2020. Available from: URL: http://doi.org/10.1093/rheumatology/keaa602
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
